Commercial success of innovative pharmaceutical assets is increasingly driven by their market access position, which plays a key role in defining both the target population and pricing. As a result, the evaluation of future market access position should be an important criterion in the early identification and screening of assets by external investors or for allocation of internal research resources. (SeeAlso see "A Call For Action: Pharma Strategies For Development Of Payor Evidence Programs" - In Vivo, 24 February, 2012..)
Unfortunately, a critical analysis of investment approaches to products in early-stage development shows that future market access position often falls...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?